Sodium Intake in Failing Heart Patients.
A Restricted Sodium Dietary Intake Reduces Hospital Admissions and Arrhythmic Burden in Patients Affected by Heart Failure With Reduced Ejection Fraction and Treated by Cardiac Resynchronization Therapy: Data From the SIRECART Registry
1 other identifier
observational
500
1 country
1
Brief Summary
Patients with heart failure (HF) have an amelioration in clinical outcomes during a restricted dietary salt intake. To date, they experienced an amelioration of functional New York Association Heart (NYHA) class, reduction of hospital admissions, and mortality, in a percentage about 60%. However, these data have been not investigated in CRTd patients with HF under a condition of restricted vs. normal dietary salt intake. In the present study authors will evaluate clinical outcomes in patients treated by Cardiac Resynchronization Therapy with a defibrillator (CRT-d) and restricted dietary salt intake (group 1) in addition to conventional heart failure (HF) therapy vs. CRTd patients under conventional dietary salt intake and conventional HF therapy (group 2). The study will be conducted during a 12-months of follow-up, to evaluate the prognosis of CRTd patients treated with restricted (n 271) vs. a matched cohort of CRTd patients treated with normal salt dietary intake in addition to conventional HF therapy (n 288). Authors' opinion is that, restricted salt intake in addition to conventional HF therapy might significantly reduce body weight and heart chambers volumes in CRTd patients, leading to a significant improvement of ejection fraction and of the 6 minutes walking test (6MWT), and to a reduction of the arrhythmic burden. Consequently, restricted salt intake in addition to conventional HF therapy might reduce hospital admissions for heart failure worsening.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2013
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2018
CompletedFirst Submitted
Initial submission to the registry
June 21, 2019
CompletedFirst Posted
Study publicly available on registry
June 26, 2019
CompletedJune 26, 2019
June 1, 2019
4.4 years
June 21, 2019
June 25, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Number of Participants with heart failure worsening events
Authors will report by telephonic interviews, clinical visits and hospital discharge schedules the patients with HF worsening events.
12 months
Study Arms (2)
salt restricted diet
In this group the patients will received after CRTD a restricted (1500 grams/daily) salt intake.
normal salt diet
In this group the patients will received after CRTD a normal (2500 grams/daily) salt intake.
Interventions
These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
Eligibility Criteria
A population of patients affected by a stable and chronic heart failure in NYHA 2-3 class, and under optimal and full medical anti-HF therapy. These patients treated with CRTd will be aged between 18 and 75 years.
You may qualify if:
- heart failure in NYHA 2-3 class;
- patients under optimal and full medical therapy for HF;
- patients treated with CRTd;
- patients without neoplastic diseases;
- patients without inflammatory sistemic diseases.
You may not qualify if:
- decompensated HF;
- unstable HF;
- patients without full anti-HF medical therapy;
- patients without indication to receive CRTd;
- patients with renal failure.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Raffaele Marfella
Naples, 80138, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
June 21, 2019
First Posted
June 26, 2019
Study Start
January 1, 2013
Primary Completion
June 1, 2017
Study Completion
January 1, 2018
Last Updated
June 26, 2019
Record last verified: 2019-06